Most exercises
included in this program require a barbell, focusing on progressive overload.
Not exact matches
Important factors that could cause actual results to differ materially from those reflected
in such forward - looking statements and that should be considered
in evaluating our outlook
include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy,
including the timing, execution, and profitability of new and maturing
programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development
programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts,
including our ability to achieve certain cost reductions with respect to the B787
program; 4) margin pressures and the potential for additional forward losses on new and maturing
programs; 5) our ability to accommodate, and the cost of accommodating, announced increases
in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft,
including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest
in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions
in the industries and markets
in which we operate
in the U.S. and globally and any changes therein,
including fluctuations
in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals,
including our ability to obtain
in a timely fashion any
required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt,
including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both
in the U.S. and abroad; 20) the effect of changes
in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction
in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging
programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue,
including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco
in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing
program; 34) the risks of doing business internationally,
including fluctuations
in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
These risks and uncertainties
include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products,
including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount of discount
required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and decreases
in treatment duration; availability of funding for state AIDS Drug Assistance
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products,
including Biktarvy; Gilead's ability to successfully commercialize its products,
including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory
programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates,
including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase
program due to changes
in its stock price, corporate or other market conditions; fluctuations
in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
If the government can guarantee certain savings
in bank accounts through the F.D.I.C., why not establish a
program that would
require that every employee own a regulated block of stock (Retirement Account) made up of stock
in the company the employee works for and, so the employee will not have all his retirement eggs
in one basket,
include in this retirement basket high rated bonds and stocks from other non-competing employee - owned companies?
(a) Schedule 2.7 (a) of the Disclosure Schedule contains a list setting forth each employee benefit plan,
program, policy or arrangement (
including any «employee benefit plan» as defined
in Section 3 (3) of the Employee Retirement Income Security Act of 1974, as amended («ERISA»)(«ERISA Plan»)-RRB-,
including, without limitation, employee pension benefit plans, as defined
in Section 3 (2) of ERISA, multi-employer plans, as defined
in Section 3 (37) of ERISA, employee welfare benefit plans, as defined
in Section 3 (1) of ERISA, deferred compensation plans, stock option plans, bonus plans, stock purchase plans, fringe benefit plans, life, hospitalization, disability and other insurance plans, severance or termination pay plans and policies, sick pay plans and vacation plans or arrangements, whether or not an ERISA Plan (
including any funding mechanism therefore now
in effect or
required in the future as a result of the transactions contemplated by this Agreement or otherwise), whether formal or informal, oral or written, under which (i) any current or former employee, director or individual consultant of the Company (collectively, the «Company Employees») has any present or future right to benefits and which are contributed to, sponsored by or maintained by the Company or (ii) the Company or any ERISA Affiliate (as hereinafter defined) has had, has or may have any actual or contingent present or future liability or obligation.
Such risks and uncertainties
include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions,
including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes
in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation
in government - sponsored
programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions,
including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals
required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing,
including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed
in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.
To be
included in UnitedHealth Group's Supplier Diversity
Program, we
require firms to be certified as minority - or women - owned businesses by a third party certification agency.
«According to a statement made by SAPPRFT today, platforms which do not have the Internet Audio - Visual
Program Transmission License,
including Weibo, Acfun and ifeng, are
required to suspend video broadcasting service as an effort to clean up political / new / commentary - related content,» Jefferies wrote
in a note.
In consultation with senior management, oversee regulatory compliance with respect to compensation matters,
including overseeing the Company's policies on structuring compensation
programs to preserve tax deductibility, and, as and when
required, establishing performance goals and certifying that performance goals have been attained for purposes of Section 162 (m) of the Internal Revenue Code.
RIAs are eligible to participate
in the
Program if they represent to Fidelity Investments that they meet the following criteria: (1) RIA is an investment adviser registered and
in good standing with the U.S. Securities and Exchange Commission and / or any applicable state securities regulatory authorities or is exempt from such registration; (2) RIA's representatives who provide services to referred clients are appropriately registered / licensed as «Investment Advisers Representatives»
in required jurisdictions; (3) RIA charges fee - based, asset - based, or flat - rate investment advisory service fees (which may
include hourly fees); (4) RIA will maintain a minimum of $ 350,000,000
in total regulatory assets under management, as reported
in response to Item 5
in Part 1A of the RIA's Form ADV, throughout the duration of RIA's participation
in the
Program; (5) RIA and all associated persons of the RIA who manage client assets or who supervise such associated persons shall at all times be covered through both Errors and Omissions Liability Insurance and Fidelity Bond Coverage; and (6) RIA maintains a minimum of two principals or officers as well as a minimum of five employees.
In 2005, the SAN standard did have critical criteria that
required a conservation
program that
included establishment and maintenance of shade trees for traditional agroforestry crops.
requires that professional development
programs shall be made available to teachers to improve instruction
in the public schools, and shall
include instruction
in incorporating character education throughout the curriculum.
Character Education: KRS 156.095
requires that professional development
programs shall be made available to teachers to improve instruction
in the public schools, and shall
include instruction
in incorporating character education throughout the curriculum.
All schools participating
in the National School Lunch
Program are
required to have a wellness policy (see Getting Junk Food Out of School: How Your School District Wellness Policy Can Help) that
includes goals for classroom food, nutrition education and more.
Every district participating
in the federal meals
program is
required to have a written policy that
includes nutrition guidelines for all foods available at school (hello, birthday cupcakes!)
In California, school districts are required to obtain insurance against liability for death, personal injury, or property loss or damage.13 Some districts in California also include in their policies specific coverage for after - school hours or for school meal program employee
In California, school districts are
required to obtain insurance against liability for death, personal injury, or property loss or damage.13 Some districts
in California also include in their policies specific coverage for after - school hours or for school meal program employee
in California also
include in their policies specific coverage for after - school hours or for school meal program employee
in their policies specific coverage for after - school hours or for school meal
program employees.
While most
programs require some amount of distance, especially
in the initial stages,
in order to allow teens to adjust to their new surroundings, a good
program will
include you as much as possible.
Mr. de Blasio,
in pursuit of his goal to build or preserve 200,000 units of affordable housing
in a decade, wanted Albany to renew the tax credit but
require all developers getting it to build affordable housing, no matter where their development was, and also wanted the
program to
include a mansion tax on sales of residences worth $ 1.75 million or more.
New York City Council Speaker Cory Johnson and Majority Leader Laurie Cumbo announced the package of 10 bills on Sunday and said the measures would be introduced this week... The proposals
include:
Requiring businesses with more than 15 employees to provide lactation spaces and refrigerators to store breast milk,
Requiring lactation rooms
in all schools, police precincts, and jails that house women or allow women visitors, Assessing the need for free and low - cost doula services
in the city, Creating a report on maternal mortality,
Requiring that inmates be able to choose the gender of their doctor,
Requiring the city to provide diapers at shelters, subsidized child care centers and other locations, Creating a study and pilot
program for on - site childcare for city employees, Allowing campaign funds to be used for certain childcare costs of candidates who are primary caregivers» http://bit.ly/2jTiAtZ
Critics note that the current
program only
requires developers to
include affordable units if their buildings are
in the «Geographic Exclusion Area» covering less than 17 percent of the five boroughs, and that it costs the city upwards of $ 1.1 billion
in foregone revenues.
For public advocate candidates participating
in the Campaign Finance Board's public matching
program, two formal, televised debates are
required for those who meet the criteria, which
include both fundraising and spending thresholds.
A handful of family - centered proposals are part of the women's agenda,
including investments
in prekindergarten and after - school
programs, increasing child care subsidies by $ 7 million, continuing the child care tax credit and
requiring all new or renovated buildings with public bathrooms to be equipped with diaper changing stations.
During his weekly «Ask the Mayor» segment, WNYC's Brian Lehrer highlighted several of de Blasio's left - wing headaches,
including the language City Council Speaker Melissa Mark - Viverito inserted into the city budget
requiring the $ 26 million
program to provide legal services to undocumented immigrants facing deportation not exclude those found guilty of violent crimes —
in defiance of de Blasio's declaration that foreign nationals convicted of rape, murder or terrorism should not benefit from city funds.
The $ 189 million spending package
includes measures to increase beds
in recovery
programs, reduce the time - length for opiate prescriptions, expand insurance coverage for detox facilities and
require prescribers to enroll
in ongoing addiction training
programs.
In September 1990, Bush and Congressional Democrats announced a compromise to cut funding for mandatory and discretionary
programs while also raising revenue; the compromise additionally
included a «pay as you go» provision that
required that new
programs be paid for at the time of implementation.
While the bill may
include language about where advertising money can be spent, if the agency chooses to advertise the
program, nothing
in the budget bill
requires the Cuomo administration to spend money on Start - Up NY advertising.
Weiss» client is looking to rezone a manufacturing site
in order to construct a nursing home at 141 Conover Street, and while the owner wouldn't be
required to build any affordable housing, the city is
including it
in the MIH
program in the event the site is later sold off to a residential developer, he explained.
At 1:30 p.m., the Senate Standing Committee on New York City Education Subcommittee will meet to discuss various amendments to education law -
including an act
in relation to
requiring certain public schools
in any city with a population over one million to offer food options during lunch, an act to direct chancellors of city school districts,
in cities having a population of one million or more, to examine and assess the feasibility of expanding the number and types of career and technical education schools and
programs within such city school districts and an act
in relation to improving educational outcomes for homeless students.
Cuomo said Tuesday the changes to the so - called «Compassionate Care Act» don't
include a ban smoking the drug and
requiring the
program to be evaluated
in five years.
Critics long complained that the
program only
required developers to
include affordable units if their buildings are
in the «Geographic Exclusion Area» covering less that 17 percent of the five boroughs, and that it cost the city upwards of $ 1.1 billion
in foregone revenues.
The new development would fall under the city's new Mandatory Inclusionary Housing
program, which
requires developers to
include a portion of affordable units
in some new construction.
He praised Mayor Bill de Blasio's proposal to reform the abatement, which would
require all projects receiving the credit across the five boroughs — rather than
in just the 16.5 percent of the city
in the
program's «geographic exclusion area» — to
include below - market apartments.
The survey also revealed a wide range of graduate curricula:
programs within astronomy, physics - astronomy, and physics departments; direct - entry Ph.D.
programs, and
programs which
required, and valued, the MSc;
programs with extensive and compulsory course requirements, and others which replace courses with minicourses, self - study courses, or extra research projects;
programs in which coursework (if any) was purely astronomy, and others which
included physics or other subjects;
programs with comprehensive exams, and others without or with an exam which was basically a defence of the Ph.D. proposal.
Shyam Sablani, associate chair of biological systems engineering at Washington State University
in Pullman, whose
program not only doesn't
require GRE scores but doesn't
include them on the application form that the faculty sees, says that the question to bring back the requirement has been raised twice
in the 10 years he has been with the department.
«The total energy from an earthquake
includes energy
required to create new cracks
in rock, energy dissipated as heat through friction, and energy elastically radiated through the earth,» reports the U.S. Geological Survey's Earthquake Hazards
Program.
In its work programs for 2014 and 2015, the commission has flagged specific topics — 16 % of all listed areas, including, for example, archeology, space medicine, and vehicle engineering — in which applicants for funding are required to describe how they will take sex and gender into accoun
In its work
programs for 2014 and 2015, the commission has flagged specific topics — 16 % of all listed areas,
including, for example, archeology, space medicine, and vehicle engineering —
in which applicants for funding are required to describe how they will take sex and gender into accoun
in which applicants for funding are
required to describe how they will take sex and gender into account.
In the self - assembly condition, participants were
required to make several hardware and software modifications to a tabletop robot,
including adding a battery and setting up the
programming software.
It is the product of a long and contentious debate
in Congress that
included efforts to eliminate the Transportation Enhancements
program (TEP), which for about 2 decades has
required states to spend a small portion of their federal transport funds on 12 types of activities,
including bike and walking paths, but also «archaeological planning & research,» and «environmental mitigation.»
The shift would likely
require Congress to change a 2011 law, called the Budget Control Act, that imposes caps on domestic spending — but Democrats
in the Senate have already said they would block any change unless it also
includes spending increases for civilian
programs.
The BRAIN Initiative K99 / R00 award is intended for individuals from diverse backgrounds (
including nationally underrepresented groups) who are working
in research areas supported by the BRAIN Initiative, who have no more than five years of postdoctoral research experience, and who
require at least 12 months of mentored research training and career development (K99 phase) before transitioning to the independent research (R00) phase of the
program.
Many
programs,
including TBB, offer need - based scholarships, but accessing those funds
requires both information and guidance, a tall order
in urban schools where a single college counselor can have 700 students on his or her caseload.
Congress
included those savings
in its fiscal 1994 budget resolution, and lawmakers are thus
required to make changes
in the
program sufficient to achieve them.
The increase came
in response to a 1986 law
requiring local summer
programs for disadvantaged youths to
include assessment of educational deficiencies and remedial assistance along with work experience.
Using the most conservative 4 % voucher advantage from our study, that means that the 801 students
in ninth grade
in the voucher
program in 2006
included 32 extra graduates who wouldn't have completed high school and gone to college if they had instead been
required to attend MPS.
In my home state of Texas, for example, the State Board for Educator Certification (SBEC) requires that in addition to the content standards specified for each grade band, the curriculum for teacher preparation programs must include 17 specific subjects of stud
In my home state of Texas, for example, the State Board for Educator Certification (SBEC)
requires that
in addition to the content standards specified for each grade band, the curriculum for teacher preparation programs must include 17 specific subjects of stud
in addition to the content standards specified for each grade band, the curriculum for teacher preparation
programs must
include 17 specific subjects of study.
The Commission will examine factors contributing to teacher recruitment and performance
including: incentives to hire and retain high - quality teachers; improvements
in the teacher evaluation system to ensure New York is implementing one of the strongest evaluation systems
in the country; the use of teacher evaluations for decisions regarding promotion, hiring and termination as
required in the teacher evaluation law; and teacher preparation, certification and education
programs to ensure that teachers are properly trained to best educate our students.
Examples of such initiatives
include the No Child Left Behind legislation
in the United States, which
required schools to demonstrate that they were making adequate yearly progress and provided escalating negative consequences for schools that were unable to do this; the creation and publication of league tables of «value - added» measures of school performance
in England; proposals to introduce financial rewards for school improvement and performance pay tied to improved test results
in Australia; and the encouragement of competition between schools under New Zealand's Tomorrow's Schools
program.
There are great outfits today (examples
include Teach For America, the Relay Graduate School of Education, New Leaders for New Schools, and the Broad Fellows
program) that assist talented individuals who want to work
in education to gain entry — as teachers, principals, leaders, and so on — without
requiring them to pass through all the traditional certification hoops.
Parent participation
in any
program activity is voluntary,
including consent for data sharing, and not
required as a condition of the child's enrollment.
In parts of this section, we propose to retain some provisions with slight revisions,
including current § 1304.40 (a)(5), which
requires staff to respect family diversity and cultural and ethnic backgrounds, and current § 1304.40 (d)(3), which
requires programs to provide parents with opportunities to participate as employees or volunteers.